Clinical Trial

Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes

Not Yet Recruiting

Summary

This study will conduct a randomized controlled trial targeting patients with type 2 diabetes and a high risk of fractures. The aim is to evaluate the intervention effect of denosumab combined with edilossobulin on patients with a high risk of osteoporotic fractures due to type 2 diabetes, as well as its impact on bone density, bone turnover indicators, the risk of new fractures, and the risk of hypocalcemia. This will provide scientific evidence for clinical diagnosis and treatment, and offer important clinical research evidence for formulating national health policies.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-07-02; most recent amendment 2026-01-18.

Trial Details

NCT Number	NCT07063797
Lead Sponsor	Peking Union Medical College Hospital
Conditions	Type 2 Diabetes, Osteoporosis, Fractures
Enrollment	358 participants
Start Date	2026-02-01
Primary Completion	2027-07-31 (estimated)
Study Completion	2027-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-21